M. Nieves Larrosa Escartín-rekin lankidetzan egindako argitalpenak (6)

2017

  1. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study

    The Lancet Infectious Diseases, Vol. 17, Núm. 7, pp. 726-734

  2. Empiric Therapy with Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results from the INCREMENT Cohort

    Clinical Infectious Diseases, Vol. 65, Núm. 10, pp. 1615-1623

  3. Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study

    International Journal of Antimicrobial Agents, Vol. 50, Núm. 5, pp. 664-672

  4. High vancomycin MICs predict the development of infective endocarditis in patients with catheter-related bacteraemia due to methicillin-resistant Staphylococcus aureus

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 7, pp. 2102-2109

2016

  1. A multinational, preregistered cohort study of β-lactam/β-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-β-lactamase-producing enterobacteriaceae

    Antimicrobial Agents and Chemotherapy, Vol. 60, Núm. 7, pp. 4159-4169

  2. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: A multinational pre-registered cohort study

    Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 6, pp. 1672-1680